The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Job Harenberg

Department of Clinical Pharmacology

Mannheim

Germany

[email]@*.uni-heidelberg.de

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Clinical Pharmacology, Mannheim, Germany. 2012
  • Prof. Dr. med. Job Harenberg, Clinical Pharmacology Mannheim, Medical Faculty Mannheim, Ruprecht- Karls University Heidelberg, E-mail:. 2009 - 2012
  • Clinical Pharmacology, Faculty of Medicine Mannheim, Mannheim, Germany. 2008 - 2011

References

  1. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. Harenberg, J., Marx, S., Weiss, C., Krämer, R., Samama, M., Schulman, S. J. Thromb. Haemost. (2012) [Pubmed]
  2. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Harenberg, J., Marx, S., Dahl, O.E., Marder, V.J., Schulze, A., Wehling, M., Weiss, C. Thromb. Haemost. (2012) [Pubmed]
  3. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network metaanalysis. Harenberg, J., Marx, S., Diener, H.C., Lip, G.Y., Marder, V.J., Wehling, M., Weiss, C. Int. Angiol (2012) [Pubmed]
  4. New anticoagulants - promising and failed developments. Harenberg, J., Marx, S., Krejczy, M., Wehling, M. Br. J. Pharmacol. (2012) [Pubmed]
  5. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Harenberg, J., Marx, S., Krämer, R., Giese, C., Weiss, C. Blood Coagul. Fibrinolysis (2011) [Pubmed]
  6. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. Harenberg, J., Krämer, R., Giese, C., Marx, S., Weiss, C., Wehling, M. J. Thromb. Thrombolysis (2011) [Pubmed]
  7. Overview on guidelines and recommendations for generic low-molecular-weight heparins. Harenberg, J. Thromb. Res. (2011) [Pubmed]
  8. Idraparinux and idrabiotaparinux. Harenberg, J. Expert. Rev. Clin. Pharmacol (2010) [Pubmed]
  9. LMWH - new mechanisms of action. Harenberg, J. Thromb. Res. (2009) [Pubmed]
  10. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Harenberg, J. Thromb. Haemost. (2009) [Pubmed]
  11. Recommendations on biosimilar low-molecular-weight heparins. Harenberg, J., Kakkar, A., Bergqvist, D., Barrowcliffe, T., Casu, B., Fareed, J., Mismetti, P., Ofosu, F.A., Raake, W., Samama, M., Schulman, S. J. Thromb. Haemost. (2009) [Pubmed]
  12. New anticoagulants in atrial fibrillation. Harenberg, J. Semin. Thromb. Hemost. (2009) [Pubmed]
  13. Development of new anticoagulants: present and future. Harenberg, J. Semin. Thromb. Hemost. (2008) [Pubmed]
 
WikiGenes - Universities